<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.cancernetwork.com/view/lung-cancer-survival-rate-climbs-to-31-although-screening-gaps-persist</loc>
      <lastmod>2026-11-17T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/selecting-patients-with-high-risk-prostate-cancer-for-perioperative-arpi-therapy</loc>
      <lastmod>2026-11-17T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Selecting Patients With High-Risk Prostate Cancer for Perioperative ARPI Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/64cu-sar-bispsma-earns-fda-breakthrough-designation-in-recurrent-prostate-cancer</loc>
      <lastmod>2026-11-17T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T14:00:00Z</news:publication_date>
        <news:title><![CDATA[64Cu-SAR-bisPSMA Earns FDA Breakthrough Designation in Recurrent Prostate Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/zipalertinib-chemo-nda-submission-completed-in-frontline-egfr-exon-20-nsclc</loc>
      <lastmod>2026-11-17T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Zipalertinib/Chemo NDA Submission Completed in Frontline EGFR Exon 20 NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-giredestrant-everolimus-for-er-her2-esr1-mutated-breast-cancer</loc>
      <lastmod>2026-11-16T22:04:03.762Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T22:04:03.762Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/who-benefits-most-from-perioperative-therapy-in-high-risk-prostate-cancer-</loc>
      <lastmod>2026-11-16T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Who Benefits Most From Perioperative Therapy in High-Risk Prostate Cancer?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/darovasertib-plus-crizotinib-yields-21-1-month-os-in-first-line-uveal-melanoma</loc>
      <lastmod>2026-11-16T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Darovasertib Plus Crizotinib Yields 21.1-Month OS in First-Line Uveal Melanoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/rocbrutinib-plus-r-chop-yields-high-complete-response-rate-in-non-gcb-dlbcl</loc>
      <lastmod>2026-11-16T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Rocbrutinib Plus R-CHOP Yields High Complete Response Rate in Non-GCB DLBCL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/belzutifan-plus-lenvatinib-earns-positive-chmp-opinion-in-advanced-ccrcc</loc>
      <lastmod>2026-11-16T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Belzutifan Plus Lenvatinib Earns Positive CHMP Opinion in Advanced ccRCC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/cretostimogene-cuts-recurrence-risk-in-intermediate-risk-high-grade-ta-nmibc</loc>
      <lastmod>2026-11-16T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Cretostimogene Cuts Recurrence Risk in Intermediate-Risk, High-Grade Ta NMIBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-approves-pertuzumab-biosimilar-in-her2-breast-cancer</loc>
      <lastmod>2026-11-16T15:00:14.845Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:00:14.845Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/remote-monitoring-strategies-for-crs-during-outpatient-bispecific-therapy</loc>
      <lastmod>2026-11-16T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Remote Monitoring Strategies for CRS During Outpatient Bispecific Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/first-line-options-for-non-clear-cell-rcc</loc>
      <lastmod>2026-11-16T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:05:00Z</news:publication_date>
        <news:title><![CDATA[First-Line Options for Non–Clear Cell RCC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-proves-crl-to-ivonescimab-chemotherapy-for-pretreated-egfr-nsclc</loc>
      <lastmod>2026-11-16T13:02:15.089Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:02:15.089Z</news:publication_date>
        <news:title><![CDATA[FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/counseling-patients-with-brain-metastases-in-rcc</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Counseling Patients With Brain Metastases in RCC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/hematology-oncology-fellowship-in-the-golden-era-of-cancer-research</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Hematology Oncology Fellowship in The “Golden Era” of Cancer Research]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/unmet-needs-and-practice-changing-takeaways</loc>
      <lastmod>2026-11-16T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-16T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Unmet Needs and Practice-Changing Takeaways]]></news:title>
      </news:news>
	</url></urlset>